MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort - PubMed (original) (raw)
doi: 10.1097/JTO.0b013e318168d9d4.
Anne-Marie Ruppert, Anne-Claire Voegeli, Agnès Neuville, Nicolas Meyer, Eric Guerin, Michèle Legrain, Bertrand Mennecier, Jean-Marie Wihlm, Gilbert Massard, Elisabeth Quoix, Pierre Oudet, Marie P Gaub
Affiliations
- PMID: 18379349
- DOI: 10.1097/JTO.0b013e318168d9d4
Free article
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort
Michèle Beau-Faller et al. J Thorac Oncol. 2008 Apr.
Free article
Abstract
Introduction: Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth factor/MET pathway, will lead to new therapeutic options for NSCLC. Furthermore, NSCLC present secondary EGFR-TKIs resistance related to exons 20 and 19 EGFR mutations or more recently to MET amplification. The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort.
Methods: We investigated 106 frozen tumors from surgically resected NSCLC patients. Genes copy number of MET and EGFR were assessed by quantitative relative real-time polymerase chain reaction and K-Ras mutations by sequencing.
Results: MET is amplified in 22 cases (21%) and deleted in nine cases (8.5%). EGFR is amplified in 31 cases (29%). K-Ras is mutated in 11 cases (10.5%). As observed for EGFR amplification, MET amplification is never associated with K-Ras mutation. MET amplification could be associated with EGFR amplification. MET amplification is not related to clinical and pathologic features. MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas.
Conclusion: In EGFR-TKIs naive NSCLC patients, MET amplification is a frequent event, which could be associated with EGFR amplification, but not with K-Ras mutation. MET amplification may identify a subset of NSCLC for new targeted therapy. It will also be important to evaluate MET copy number to properly interpret future clinical trials.
Similar articles
- Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 - Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P. Lim EH, et al. J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28. J Thorac Oncol. 2009. PMID: 19096301 - Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chen YT, Chang JW, Liu HP, Yu TF, Chiu YT, Hsieh JJ, Chen YT, Chen YR, Wu HD, Huang SF. Chen YT, et al. J Thorac Oncol. 2011 Dec;6(12):2027-35. doi: 10.1097/JTO.0b013e3182307e92. J Thorac Oncol. 2011. PMID: 22052229 - KRAS mutation: should we test for it, and does it matter?
Roberts PJ, Stinchcombe TE. Roberts PJ, et al. J Clin Oncol. 2013 Mar 10;31(8):1112-21. doi: 10.1200/JCO.2012.43.0454. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401440 Review. - Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
Wang S, Wang Z. Wang S, et al. Clin Oncol (R Coll Radiol). 2015 Jan;27(1):30-9. doi: 10.1016/j.clon.2014.09.014. Epub 2014 Oct 14. Clin Oncol (R Coll Radiol). 2015. PMID: 25445553 Review.
Cited by
- c-MET as a potential therapeutic target and biomarker in cancer.
Sierra JR, Tsao MS. Sierra JR, et al. Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. doi: 10.1177/1758834011422557. Ther Adv Med Oncol. 2011. PMID: 22128285 Free PMC article. - Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. Ariyawutyakorn W, et al. J Cancer. 2016 Mar 20;7(6):633-49. doi: 10.7150/jca.12663. eCollection 2016. J Cancer. 2016. PMID: 27076844 Free PMC article. Review. - Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.
Smyth EC, Sclafani F, Cunningham D. Smyth EC, et al. Onco Targets Ther. 2014 Jun 12;7:1001-14. doi: 10.2147/OTT.S44941. eCollection 2014. Onco Targets Ther. 2014. PMID: 24959087 Free PMC article. Review. - Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.
Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB. Baldacci S, et al. Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1. Oncotarget. 2017. PMID: 29285237 Free PMC article. - Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR. Dziadziuszko R, et al. J Thorac Oncol. 2012 Feb;7(2):340-7. doi: 10.1097/JTO.0b013e318240ca0d. J Thorac Oncol. 2012. PMID: 22237262 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous